Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 PatientsGian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2020
Standardization of <sup>18</sup>F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple MyelomaElena Zamagni, Cristina Nanni, Luca Dozza, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
British Journal of Haematology|December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE studyFederico Stella, Annalisa Chiappella, Martina Magni, et al.
Annals of Hematology|September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working GroupGregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood|September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patientsSara Bringhen, Alessandra Larocca, Davide Rossi, et al.
BMC Cancer|November 25, 2020
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patientsLuca Castagna, Alessandro Busca, Stefania Bramanti, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Pageof 16